Are prexitinib and platinib the same medicine?

Presitinib and platinib are actually the same drug, but they have different translations. The drug is a RET kinase inhibitor that is used to treat cancers such as non-small cell lung cancer and medullary thyroid cancer.

Presitinib and platinib are two different translations of the same drug. Internationally, the drug is usually referred to by its English name Pralsetinib. In the Chinese environment, due to differences in translation, different translated names may appear, which leads to the existence of two names: prexitinib and platinib.

Presitinib (Platinib) is a RET kinase inhibitor. RETkinase is a protein that plays a key role in a variety of cancers. This drug blocks the growth and spread of cancer cells by inhibiting the activity of RET kinase, thereby achieving the purpose of treating cancer.

Prexitinib (Platinib) is mainly used to treat non-small cell lung cancer and medullary thyroid cancer. Especially for RET fusion-positive non-small cell lung cancer and RET mutated medullary thyroid cancer, the drug has shown significant efficacy.

Presitinib (Platinib) is developed byBlueprint Medicines, a biopharmaceutical company focused on developing precision oncology drugs. The drug has been approved for marketing in many countries and regions around the world, providing new treatment options for cancer patients.

As an innovative drug, prexitinib (Platinib) has a relatively high market price. The specific price varies by region and sales channel, but usually the price of each bottle (100mg*120pills) is around tens of thousands of yuan. However, for many cancer patients, this drug offers new treatment opportunities and hope.